Analysts expect Zevra Therapeutics, Inc. to report revenue of 38.85 M for Q3 26, against a range of 36.27 M to 41.43 M. The most recent reported quarter, Q2 26, came in at 39.66 M, a 20.6% beat against the 32.89 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 3.69 M | 12.00 M | 20.40 M | 25.88 M | 26.06 M | 34.10 M | 36.22 M | 39.66 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 5.00 M | 9.21 M | 17.23 M | 22.61 M | 30.48 M | 29.12 M | 36.57 M | 34.55 M | 41.43 M | 41.27 M | 46.92 M | 45.70 M | 67.19 M | 97.45 M | 39.52 M | 34.79 M | ||||||||||
| Low Estimate | 4.34 M | 8.18 M | 15.45 M | 19.74 M | 25.85 M | 24.59 M | 30.89 M | 31.23 M | 36.27 M | 34.75 M | 40.23 M | 37.86 M | 57.63 M | 80.34 M | 35.41 M | 32.70 M | ||||||||||
| Consensus Estimate | 4.67 M | 8.70 M | 16.34 M | 21.18 M | 28.17 M | 26.86 M | 33.73 M | 32.89 M | 38.85 M | 38.01 M | 43.58 M | 41.78 M | 62.41 M | 88.89 M | 37.47 M | 33.74 M |
Analysts expect Zevra Therapeutics, Inc. to report earnings per share of 0.15 for Q3 26, against a range of 0.14 to 0.16. The most recent reported quarter, Q2 26, came in at 0.14, a 40.0% beat against the 0.10 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.69 | -0.67 | -0.06 | 1.21 | -0.01 | 0.19 | 0.60 | 0.14 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.40 | -0.36 | -0.18 | 2.59 | -0.03 | 0.05 | 0.09 | 0.11 | 0.16 | 0.18 | 0.24 | 0.29 | 0.04 | 0.24 | 0.51 | 0.48 | ||||||||||
| Low Estimate | -0.46 | -0.40 | -0.20 | 2.17 | -0.03 | 0.05 | 0.07 | 0.09 | 0.14 | 0.16 | 0.22 | 0.27 | 0.04 | 0.20 | 0.45 | 0.42 | ||||||||||
| Consensus Estimate | -0.43 | -0.38 | -0.19 | 2.38 | -0.03 | 0.05 | 0.08 | 0.10 | 0.15 | 0.17 | 0.23 | 0.28 | 0.04 | 0.22 | 0.48 | 0.45 |
Pull Wall Street consensus for Zevra Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ZVRA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ZVRA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ZVRA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();